Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

  • Hamid, Anis (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date26/04/2320/04/26

Keywords

  • clinical trial
  • HER2
  • genetic abberation
  • Metastatic cancer